ストックスクリーナーアプリを入手
0.6139
10.09%
-0.0689
アフターアワーズ：
.64
0.0261
+4.25%
Century Therapeutics Inc (IPSC) 最新ニュース
Layoff Tracker: CRISPR, Cytiva Laying Off Employees - BioSpace
Century Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Century Therapeutics faces Nasdaq delisting over share price - Investing.com
Century Therapeutics Receives Nasdaq Notice For Bid Price Deficiency -February 28, 2025 at 04:20 pm EST - Marketscreener.com
Century Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
Century Therapeutics CEO sells shares worth $27,179 - Investing.com
Century Therapeutics CEO sells shares worth $27,179 By Investing.com - Investing.com UK
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MSN
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00 - Defense World
Leerink Partnrs Has Strong Forecast for IPSC FY2024 Earnings - Defense World
Brokers Offer Predictions for IPSC FY2029 Earnings - Defense World
FY2029 Earnings Estimate for IPSC Issued By Leerink Partnrs - MarketBeat
Ratios Reveal: Breaking Down Century Therapeutics Inc (IPSC)’s Financial Health - The Dwinnex
Quarterly Snapshot: Quick and Current Ratios for Janux Therapeutics Inc (JANX) - The Dwinnex
Analyzing Telephone And Data Systems, Inc (TDS) After Recent Trading Activity - Knox Daily
Balance Sheet Insights: BioXcel Therapeutics Inc (BTAI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Century Therapeutics COO Farid Adrienne sells $822 in stock - MSN
Century Therapeutics SVP sells shares worth $273 to cover taxes - MSN
Century Therapeutics COO Farid Adrienne sells $822 in stock By Investing.com - Investing.com Canada
Century Therapeutics SVP sells shares worth $273 to cover taxes By Investing.com - Investing.com Canada
Financial Metrics Exploration: Understanding Century Therapeutics Inc (IPSC) Through Ratios - The Dwinnex
JPMorgan Chase & Co. Has $123,000 Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Growth in Short Interest - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus PT from Brokerages - Defense World
Barclays PLC Increases Stock Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics (NASDAQ:IPSC) Receives "Buy" Rating from Guggenheim - MarketBeat
HC Wainwright Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - MarketBeat
Century Therapeutics launches cell therapy trial for autoimmune diseases - MSN
4 Analysts Have This To Say About Century Therapeutics - Benzinga
Century Therapeutics Announces Investigator-Initiated Phase - GlobeNewswire
Century Therapeutics Pioneers First iPSC-Derived NK Cell Therapy Trial for Autoimmune Diseases - StockTitan
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Increases By 14.0% - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 14.0% in December - Defense World
Jane Street Group LLC Sells 62,588 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
JPMorgan Chase & Co. Boosts Stake in Costamare Inc. (NYSE:CMRE) - Defense World
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MyChesCo
3.13%
1.23%
大文字化:
|
ボリューム (24 時間):